Zaffran, I., Landolina, N., Gaur, P., Lenac Roviš, T., Jonjić, S., Mandelboim, O. ... Levi Schaffer, F. (2022). Activation of CEACAM1 with an agonistic monoclonal antibody results in inhibition of melanoma cells. Cancer Gene Therapy, 29. (11), 1676-1685. doi: 10.1038/s41417-022-00486-x
Zaffran, Ilan, et al. "Activation of CEACAM1 with an agonistic monoclonal antibody results in inhibition of melanoma cells." Cancer Gene Therapy, vol. 29, br. 11, 2022, str. 1676-1685. https://doi.org/10.1038/s41417-022-00486-x
Zaffran, Ilan, Nadine Landolina, Pratibha Gaur, Tihana Lenac Roviš, Stipan Jonjić, Ofer Mandelboim, Bernhard B. Singer i Francesca Levi Schaffer. "Activation of CEACAM1 with an agonistic monoclonal antibody results in inhibition of melanoma cells." Cancer Gene Therapy 29, br. 11 (2022): 1676-1685. https://doi.org/10.1038/s41417-022-00486-x
Zaffran, I., et al. (2022) 'Activation of CEACAM1 with an agonistic monoclonal antibody results in inhibition of melanoma cells', Cancer Gene Therapy, 29(11), str. 1676-1685. doi: 10.1038/s41417-022-00486-x
Zaffran I, Landolina N, Gaur P, Lenac Roviš T, Jonjić S, Mandelboim O, i sur.. Activation of CEACAM1 with an agonistic monoclonal antibody results in inhibition of melanoma cells. Cancer Gene Therapy [Internet]. 09.06.2022. [pristupljeno 11.10.2024.];29(11):1676-1685. doi: 10.1038/s41417-022-00486-x
I. Zaffran, et al., "Activation of CEACAM1 with an agonistic monoclonal antibody results in inhibition of melanoma cells", Cancer Gene Therapy, vol. 29, br. 11, str. 1676-1685, Lipanj 2022. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:184:520126. [Citirano: 11.10.2024.]